RPRX - Eisai and Lilly among top H1 gainers in big pharma as Viatris and Merck trail

gerenme/iStock via Getty Images The advancements in treatments for Alzheimer’s disease have spurred gains among large-cap pharmaceutical companies in the first half of 2021. Eisai ([[ESALY]] -0.9%) and Eli Lilly ([[LLY]] +0.7%) are among the five leading gainers in the pharmaceutical subsector with both rising over a third to claim first and third positions in the list. Early this month, Eisai joined Biogen in winning FDA approval for Aduhelm (aducanumab) the first Alzheimer’s therapy in nearly two decades. In a few days, Lilly won the regulator’s Breakthrough Therapy designation for donanemab its Alzheimer’s asset for which the company expects to file a marketing application later this year. Meanwhile, AstraZeneca ([[AZN]] +0.8%) ADRs have climbed ~19.4% in H1 2021 to reach the fifth position in the list despite its battle over the safety concerns linked to its COVID-19 vaccine.   Bausch Health Companies ([[BHC]] +2.9%) and Novo Nordisk ([[NVO]] +0.7%) ranked second and fourth with ~41.0% and

For further details see:

Eisai and Lilly among top H1 gainers in big pharma as Viatris and Merck trail